AJP - Renal Physiology, Vol 251, Issue 1 1-11, Copyright © 1986 by American Physiological Society

ARTICLES

Platelet-activating factor and the kidney

D. Schlondorff and R. Neuwirth

Platelet-activating factor (PAF) represents a group of phospholipids with the basic structure of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine. A number of different cells are capable of producing PAF in response to various stimuli. The initial step of PAF formation is activation of phospholipase A2 in a calcium-dependent manner, yielding lyso-PAF. During this step arachidonic acid is also released and can be converted to its respective cyclooxygenase and lipoxygenase products. The lyso-PAF generated is then acetylated in position 2 of the glycerol backbone by a coenzyme A (CoA)-dependent acetyltransferase. An additional pathway may exist whereby PAF is generated de novo from 1-alkyl-2-acetyl-sn-glycerol by phosphocholine transferase. PAF inactivation in cells and blood is by specific acetylhydrolases. PAF exhibits a variety of biological activities including platelet and leukocyte aggregation and activation, increased vascular permeability, respiratory distress, decreased cardiac output, and hypotension. In the kidney PAF can produce decreases in blood flow, glomerular filtration, and fluid and electrolyte excretion. Intrarenal artery injection of PAF may also result in glomerular accumulation of platelets and leukocytes and mild proteinuria. PAF increases prostaglandin formation in the isolated kidney and in cultured glomerular mesangial cells. PAF also causes contraction of mesangial cells. Upon stimulation with calcium ionophore the isolated kidney, isolated glomeruli and medullary cells, and cultured mesangial cells are capable of producing PAF. The potential role for PAF in renal physiology and pathophysiology requires further investigation that may be complicated by 1) the multiple interactions of PAF, prostaglandins, and leukotrienes and 2) the autocoid nature of PAF, which may restrict its action to its site of generation.

This article has been cited by other articles:

				R. K. Handa, J. W. Strandhoy, C. E. Giammattei, and S. E. Handa Platelet-activating factor and solute transport processes in the kidney Am J Physiol Renal Physiol, February 1, 2003; 284(2): F274 - F281. [Abstract] [Full Text] [PDF]

				G. Montrucchio, G. Alloatti, and G. Camussi Role of Platelet-Activating Factor in Cardiovascular Pathophysiology Physiol Rev, October 1, 2000; 80(4): 1669 - 1699. [Abstract] [Full Text] [PDF]

				S. ERNEST and E. BELLO-REUSS Secretion of Platelet-Activating Factor Is Mediated by MDR1 P-Glycoprotein in Cultured Human Mesangial Cells J. Am. Soc. Nephrol., November 1, 1999; 10(11): 2306 - 2313. [Abstract] [Full Text]

				S. G. Greenberg and K. E. Clark Hemodynamic effects of platelet-activating factor in nonpregnant and pregnant sheep Am J Physiol Regulatory Integrative Comp Physiol, October 1, 1999; 277(4): R996 - R1001. [Abstract] [Full Text] [PDF]